Isotretinoin for acne and rosacea

Kendra D. Watson, Rachel Y. Miest, Megha M. Tollefson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalSeminars in Cutaneous Medicine and Surgery
Volume35
Issue number2
DOIs
StatePublished - Jun 1 2016

Fingerprint

Rosacea
Isotretinoin
Government Regulation
Acne Vulgaris
Mood Disorders
Inflammatory Bowel Diseases
Fear
Recurrence
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)
  • Dermatology

Cite this

Isotretinoin for acne and rosacea. / Watson, Kendra D.; Miest, Rachel Y.; Tollefson, Megha M.

In: Seminars in Cutaneous Medicine and Surgery, Vol. 35, No. 2, 01.06.2016, p. 79-86.

Research output: Contribution to journalArticle

Watson, Kendra D. ; Miest, Rachel Y. ; Tollefson, Megha M. / Isotretinoin for acne and rosacea. In: Seminars in Cutaneous Medicine and Surgery. 2016 ; Vol. 35, No. 2. pp. 79-86.
@article{0148f9f204c94a778d6b87ef74cddd8f,
title = "Isotretinoin for acne and rosacea",
abstract = "Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.",
author = "Watson, {Kendra D.} and Miest, {Rachel Y.} and Tollefson, {Megha M.}",
year = "2016",
month = "6",
day = "1",
doi = "10.12788/j.sder.2016.023",
language = "English (US)",
volume = "35",
pages = "79--86",
journal = "Seminars in Cutaneous Medicine and Surgery",
issn = "1085-5629",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Isotretinoin for acne and rosacea

AU - Watson, Kendra D.

AU - Miest, Rachel Y.

AU - Tollefson, Megha M.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.

AB - Isotretinoin is a revolutionary medicine for the treatment of acne vulgaris, with new studies showing evidence of excellent clinical outcomes in treating rosacea. After 30 years of clinical experience, new insights are being gained into dosing strategies, recurrence prevention, and dose-related side effects. Previous controversial associations with inflammatory bowel diseases and mood disorders have hampered the use of this medication in some clinical situations, with new evidence disproving these claims. The teratogenicity of this medication mandates iPLEDGE compliance with government regulations. Clinicians should be knowledgeable about this medication including its side effects, teratogenicity, and its controversies in order to adequately counsel patients, dissuade fears, and obtain the best clinical outcome when treating acne and rosacea.

UR - http://www.scopus.com/inward/record.url?scp=84988476677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988476677&partnerID=8YFLogxK

U2 - 10.12788/j.sder.2016.023

DO - 10.12788/j.sder.2016.023

M3 - Article

C2 - 27416313

AN - SCOPUS:84988476677

VL - 35

SP - 79

EP - 86

JO - Seminars in Cutaneous Medicine and Surgery

JF - Seminars in Cutaneous Medicine and Surgery

SN - 1085-5629

IS - 2

ER -